Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Strezova, Ana; Díez‐Domingo, Javier; Shawafi, Kamal Al; Tinoco, Juan Carlos; Shi, M.; Pirrotta, Paola; Mwakingwe-Omari, Agnes; Adams, Michael; Ahonen, Anitta; Andrews, Charles P.; Athan, Eugene; Jose-Fernando, Barba-Gómez; Barbanti, Piero; Barberan, Elisabeth; Baty, Alain; Bengtsson, Niklas; Berger-Roscher, Juergen; Blom, Katarina Berndtsson; Beytout, Jean; Boucher, Loïc; Boutry, Céline; Boye, Alain; Brault, François; Breger, Laurie; Cuixart, Carles Brotons; Caso, Covadonga; Cerna, Christine; Cheng, Huey‐Shinn; Cheong, Hee Jin; Choo, Eun Ju; Cunha, Clóvis Aquino de Freitas; Cunningham, Anthony L.; Curiac, Dan; Daguzan, Benoit; Antje, Dahmen; Datta, Susan; Desole, Maria Giuseppina; Paolo, Emmanuel Di; Dionne, Marc; Dítě, Petr; Dutz, Jan P.; Earl, John; Eckermann, Tamara; William, E; Eremenko, Jurij; Esen, Meral; Eto, Takashi; Fabré, Xavier Farrés; Farrington, Cecil; Ferguson, Murdo; Ferrand, Pierre André; Finneran, Matthew; Francyk, David; Freedman, Marshall; Freeman, George; Freire, Antônio Tarcísio; Gál, Péter; Gauthier, Jean-Sebastien; Gerlach, Beatrice; Ghesquière, Wayne; Gorfinkel, Iris; Christine, Grigat; Grosskopf, Josef; Hamann, Mónika Inés; Hanrion, Pascal; Hartley, Paul; Hastie, Andrew; Heaton, Ken; Himpel-Boenninghoff, Agnes; Horacek, Thomas; Hui, David Shu Cheong; Huong, Yieng; Hwang, Shinn‐Jang; Icardi, Giancarlo; Illies, Gabriele; Irimajiri, Junya; Wilson, Janet A.; Jambrecina, Alen; Avelino‐Silva, Thiago Junqueira; Kalema, George; Kim, Hyo Youl; Klein, Christiane; Kleinecke, Uwe; Hans-Joachim, Koenig; Kokko, Satu; Kosina, Pavel; Koski, Susanna; Koskinen, Pekka; Kropp, Maximilian; Kuroki, Rie; Laajalahti, Outi; Leblond, Pierre; Jacob, Louis; Lee, Jin-Soo; Levins, Peter; Lipetz, Robert; Liu, Bo; Liu, Chiu-Shong; Lundvall, Martin; Magimaiseelan, Luci; Manning, Mary Beth; Markkula, Jukka; Martin, Frederick N.; Piera, Pyrene Martínez; Damien, McNally; McNeil, Shelly; Guglielmo, Migliorino; Moeckesch, Beate; Morscher, Stephan; Michael, Mueller; Munir, Abul Kashem; Oliveira, Cláudia Murta de; Kenjiro, Nakamura; Pérez, Silvia Narejos; Naritomi, Yuji; Nault, Patrice; Neto, José Luiz Costa; López, Concepción Núñez; Ogata, Hiroaki; Olsson, Åke; Paavola, Pauliina; Park, Dae Won; Janice, Patrick; Pauksens, Karlis; Vera, Mercè Pérez; Peltonen, L; Plassmann, Georg; Põder, Airi; Poling, Terry; Pretswell, Carol; Purnell-Mullick, Samir; Raad, George; Redmond, T. Michael; Remaud, Philippe; Riffer, Ernie; Robert, P. C.; Badia, Alex Rodríguez; Pinta, María Luisa Rodriguez de la; Rombo, Lars; Robert, René; Rozen, Shari; Saillard, Dominique; Salaun, Bruno; Berglund, Johan; Sauter, Joachim; Schaefer, Axel; Schenkenberger, Isabelle; Juergen, Schmidt; Schmitt, Bernhard; Christian, Schubert; Schuind, Anne; Schwarz, Tino; Seppa, Ilkka; Sha, Edmund Kwok Yiu; Shockey, Gerald; Shoffner, Sylvia; Sirnela-Rif, Elina; Staniscia, Tommaso; Sueki, Hirohiko; Suzuki, Shohachi; Taminau, Denis; Guy, Tellier; Riera, Manuel Terns; Toma, Aurel; Nicole, Toursarkissian; Turner, M.; Ukkonen, Benita; Morató, Anna Vilella; Wachter, Juergen; Webster, Brian; Karl, Wilhelm; Jonathan, Wilson; Yeo, Wilfred; Yu, Chong‐Jen; Zahaf, Toufik; Irina, Zahharova; Zerbini, Cristiano Augusto de Freitas

doi:10.1093/ofid/ofac485

Cited by 46 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have reported efficacy and real-world effectiveness of RZV against HZ (81.6% up to 10 years post-vaccination and 76% up to 4 years post-vaccination in fully vaccinated individuals, respectively). 113 , 114 While further long-term data are necessary, these available data suggest it may be beneficial to target adults at an earlier age than that of those most likely to receive HZ vaccination currently. The impact of varicella vaccination on HZ epidemiology was beyond the scope of the current SLR.…”

Section: Discussionmentioning

confidence: 99%

A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific

Chen,

Abrahamson,

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Herpes zoster (HZ) is a painful rash which typically affects older adults. This is of concern in Asia-Pacific given its aging population. As HZ epidemiology and burden are evolving, this systematic literature review aimed to update the current understanding of HZ burden and associated costs for selected Asia-Pacific locales. MEDLINE and Embase were searched for English articles of HZ studies conducted in Australia, China, Hong Kong, Japan, Korea, New Zealand, Singapore, and Taiwan. Eligible outcomes included HZ incidence and prevalence, occurrence of HZ-related complications, healthcare resource utilization, costs, and HZ-associated quality of life outcomes. This paper focused on HZ data in the general adult population ( N = 90 articles). Substantial HZ-related disease and economic burden were observed in these locales, consistent with global trends. These findings reinforce the increasing burden of HZ and need for preventive strategies, which may include raising awareness and encouraging timely vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific

Chen,

Abrahamson,

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Recently, the 10-year follow-up data of patients included in the initial studies of the vaccine (ZOE-50 and ZOE-70) were released 40 , 41 , demonstrating persistent serological efficacy (both cellular and humoral immunity) as well as clinical efficacy 42 . Regarding AEs of the recombinant vaccine, these were mostly local, mild, and self-limited.…”

Section: Herpes Zoster (Shingles) Vaccinementioning

confidence: 99%

Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk

García-Zamora,

Pulido

2024

Arch Peru Cardiol Cir Cardiovasc

View full text Add to dashboard Cite

Las enfermedades cardiovasculares representan la primera causa de muerte en adultos de todo el mundo. Desde hace décadas se ha documentado que las infecciones en general, y particularmente las que involucran el aparato respiratorio, incrementan el riesgo de eventos cardiovasculares, cerebrovasculares y la mortalidad por todas las causas. Los mecanismos por los que las infecciones incrementan los eventos cardiovasculares son complejos, e incluyen la activación del sistema inmune, la inflamación sistémica, estados de hipercoagulabilidad, activación del sistema simpático y el aumento de la demanda miocárdica de oxígeno. En las infecciones respiratorias se agrega la hipoxemia. Estos mecanismos se interrelacionan, generando disfunción endotelial y accidentes de placa, y/o depresión miocárdica e insuficiencia cardíaca. Estos mecanismos pueden producir eventos cardiovasculares de novo o descompensar patologías preexistentes. Existe evidencia contundente de que las vacunas contra influenza, neumococo, herpes-zoster, COVID-19 y virus sincicial respiratorio son seguras en personas con factores de riesgo cardiovascular o enfermedad cardiovascular establecida. Incluso, la vacuna contra influenza ha demostrado ser segura cuando se administra en el período agudo de un síndrome coronario agudo en individuos que reciben angioplastia. Además de esto, estas intervenciones reducen la incidencia de eventos cardiovasculares en personas con riesgo cardiovascular incrementado. Sin embargo, las tasas de vacunación son marcadamente subóptimas. En el presente manuscrito se revisa la evidencia de la relación entre infecciones y eventos cardiovasculares. Además, se examina el rol de las inmunizaciones como una herramienta para reducir estos eventos y disminuir el riesgo cardiovascular residual. Finalmente, se plantea la necesidad de optimizar las tasas de vacunación en personas con cardiopatías.

show abstract

“…Vaccines targeting varicella-zoster, including Varivax for varicella and Shingrix and Zostavax for herpes zoster, are accessible options for preventing herpes zoster [ 74 ]. The recombinant zoster vaccine (RZV) has exhibited sustained high efficacy against herpes zoster, remaining effective approximately 10 years post-vaccination, with a clinically acceptable safety profile [ 75 ]. Studies have confirmed the effectiveness of the zoster vaccine in preventing incident herpes zoster in older individuals with chronic kidney disease [ 76 ].…”

Section: Prevention Of Herpes Zoster and Its Complicationsmentioning

confidence: 99%

Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination

Yamaoka-Tojo,

Tojo

2024

Vaccines

View full text Add to dashboard Cite

Herpes zoster, induced by the reactivation of the varicella-zoster virus (VZV), is a unilaterally distributed vesicular rash that can cause multiple complications. VZV not only causes neurological problems, including postherpetic neuralgia and ocular zoster, but also causes inflammatory vasculopathy and increases the incidence of hemorrhagic or ischemic complications. Therefore, understanding the association between the development of herpes zoster and the subsequent occurrence of acute stroke or cardiovascular diseases, including myocardial infarction and heart failure, is of great interest. Conversely, many risk factors are involved in the development of herpes zoster. Recently, it has become clear that aging, insufficient immune function, and diseases related to lifestyle habits (for example, stroke and cardiovascular disease), can trigger the onset of herpes zoster. Preventing the onset of herpes zoster, which substantially reduces quality of life, will lead to lower medical costs for countries and extend healthy life expectancy for general populations. Thus, because herpes zoster is a vaccine-preventable disease, active vaccination is recommended for high-risk groups. This review summarizes the association between herpes zoster and cardiovascular disease and vaccination against herpes zoster as a useful disease management and prevention measure for cardiovascular disease.

show abstract

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Cited by 46 publications

References 9 publications

A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific

A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific

Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk

Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination

Contact Info

Product

Resources

About